Cor Vasa 2015, 57(2):267-268

Zmírnění příznaků a ochrana myokardu při léčbě Preductalem MR u pacientů s reziduální anginou pectoris po PCI

Petr Widimský
III. interní-kardiologická klinika, Kardiocentrum 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha

Published: April 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský P. Zmírnění příznaků a ochrana myokardu při léčbě Preductalem MR u pacientů s reziduální anginou pectoris po PCI. Cor Vasa. 2015;57(2):267-268.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. N. Fillmore, J. Mori, G.D. Lopaschuk, Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy, British Journal of Pharmacology 171 (2014) 2080-2090. Go to original source... Go to PubMed...
    2. S. Peng, M. Zhao, J. Wan, et al., The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials, International Journal of Cardiology 177 (2014) 780-785. Go to original source... Go to PubMed...
    3. G. Fragasso, G. Perseghin, F. De Cobelli, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure, European Heart Journal 27 (2006) 942-948. Go to original source... Go to PubMed...
    4. K. Tsioufis, G. Andrikopoulos, A. Manolis, Trimetazidine and Cardioprotection: Facts and Perspectives, Angiology 2014 Apr 8 [Epub ahead of print] Go to original source... Go to PubMed...
    5. W.E. Boden, R.A. O'Rourke, K.K. Teo, et al.; COURAGE Trial Research Group, Optimal medical therapy with or without PCI for stable coronary disease, New England Journal of Medicine 356 (2007) 1503-1516. Go to original source... Go to PubMed...
    6. X. Xu, W. Zhang, Y. Zhou, et al., Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up, Clinical Drug Investigation 34 (2014) 251-258. Go to original source... Go to PubMed...
    7. M. Shehata, Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention, American Journal of Cardiology 114 (2014) 389-394. Go to original source... Go to PubMed...
    8. J. Chen, S. Zhou, J. Jin, et al., Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: A 1-year prospective follow-up study, International Journal of Cardiology 174 (2014) 634-639. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes